Corcept Therapeutics
Trade Corcept Therapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About CORT
Corcept Therapeutics, Inc. engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B.
CORT Key Statistics
Stock Snapshot
The current Corcept Therapeutics(CORT) stock price is $114.49, with a market capitalization of 16.18B. The stock trades at a price-to-earnings (P/E) ratio of 222.00.
During the trading session on 2026-07-31, Corcept Therapeutics(CORT) shares reached a daily high of $118.53 and a low of $111.79. At a current price of $114.49, the stock is +2.4% higher than the low and still -3.4% under the high.
Trading activity shows a volume of 1.81M, compared to an average daily volume of 1.6M.
Over the past 52 weeks, Corcept Therapeutics(CORT) stock has traded between a high of $122.21 and a low of $28.66.
Over the past 52 weeks, Corcept Therapeutics(CORT) stock has traded between a high of $122.21 and a low of $28.66.
CORT News
Founder led companies can offer a different kind of anchor when inflation trends are mixed, central banks keep investors guessing on rates, and energy and credi...
Global growth signals look uneven, inflation trends are mixed, and central banks are keeping investors on their toes. In this kind of backdrop, many readers are...
With growth signals mixed across Europe, inflation still shaping central bank decisions and energy prices on every investor’s radar, leadership quality matters...
Analyst ratings
83%
of 6 ratingsMore CORT News
...
Piper Sandler raised the firm’s price target on Corcept Therapeutics (CORT) to $165 from $88 and keeps an Overweight rating on the shares. The firm notes Corcep...
Revenue and EPS Sail Past Analyst Targets The California-based biopharmaceutical company reported second-quarter revenue of $256.1 million for the period ended...
Corcept Therapeutics (CORT) is back in focus after the FDA approved Lifyorli, its relacorilant combination for platinum resistant ovarian cancer. This developme...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.